Navigation Links
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Trius Therapeutics, Inc. - TSRX
Date:7/31/2013

NEW YORK, July 31, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of Trius Therapeutics, Inc. ("Trius" or the "Company") (NASDAQ: TSRX) (ISIN: US89685K1007) (CUSIP: 89685K100) concerning the proposed acquisition of Trius by Cubist Pharmaceuticals, Inc. in a transaction valued at $818 million.

The investigation concerns whether the Trius directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value.  Under the terms of the agreement, Trius shareholders will be entitled to receive $13.50 per share in cash for each share of Trius common stock. In addition to the upfront cash payment, each Trius stockholder will receive one Contingent Value Right, entitling the holder to receive an additional cash payment of up to $2.00 for each share they own if certain commercial sales milestones are achieved.  However, the price to Revenue and Book Value multiples are below the averages of comparable transactions and at least one analyst has set a target price of $20.00 per share for Trius common stock.

Trius shareholders seeking more information about this acquisition are advised to contact Robert Willoughby at rswilloughby@pomlaw.com or 212-661-1100 or 888-476-6529, ext. 237.

The firm is also investigating actions on behalf of shareholders for the following companies:  Hilltop Community Bancorp, Inc., Dole Food Company, Inc., and Cooper Tire & Rubber Company.

The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 75 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of defrauded investors. See www.pomerantzlaw.com.

CONTACT:
Robert Willoughby
Pomerantz Grossman Hufford Dahlstrom & Gross LLP
212-661-1100 ext. 237
rswilloughby@pomlaw.com


'/>"/>
SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Royalty Pharma Notes Elan Sales Process Offers Shareholders No Certainty
2. Adamis Pharmaceuticals CEO Provides Update for Shareholders
3. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection with the Sale of the Company to OPKO Health, Inc.
4. 3SBio Inc. Adjourns Extraordinary General Meeting of Shareholders
5. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
6. Hadasit Bio-Holdings CEO Letter to Shareholders
7. Medifirst Solutions, Inc. Announces Further Update To Shareholders
8. Letter from Alliqua CEO, Dave Johnston, to Shareholders
9. TPI to Hold 2012 Shareholder Annual Meeting on May 8, 2013 In New York City
10. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
11. Cell Therapeutics, Inc.s (CTI) Board of Directors Approves Amendment of Shareholder Rights Plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)...  Northwest Biotherapeutics, Inc. (OTCQB: NWBO) ("NW Bio"), a ... operable and inoperable solid tumor cancers, announced today that ... NW Bio, will present at the Phacilitate Immunotherapy World ... Regency Hotel in Miami, Florida . ... "New Therapeutic Approaches – Expanding the Reach of Cancer ...
(Date:1/18/2017)... ... January 18, 2017 , ... ... interconnect using USB or PCI Express, announced the ZEM5310 USB 3.0 FPGA Module, ... into a compact business-card sized form factor suitable for prototyping, testing, and production-ready ...
(Date:1/18/2017)... Mass. , Jan. 18, 2017 ... applying mechanistic modeling to drug research and development, ... PhD, Co-Founder, President, and CEO of Applied BioMath, ... for Informatics and Modeling (BAGIM) Meeting on Thursday ... Cambridge , MA.   Dr. Burke,s ...
(Date:1/18/2017)... MA (PRWEB) , ... January 18, 2017 , ... ... today that Dr. Dante Leven successfully implanted SpineFrontier’s A-CIFT™ Solofuse-P™. The operation took ... Center in Valley Stream, NY. The procedure was an anterior cervical discectomy and ...
Breaking Biology Technology:
(Date:12/8/2016)... Dec. 8, 2016  Singulex, Inc., the leader in ... entered into a license and supply agreement with Thermo ... agreement provides Singulex access to Thermo Scientific BRAHMS PCT ... is used to diagnose systemic bacterial infection and ... to aid in assessing the risk of critically ...
(Date:12/7/2016)... -- BioCatch , the global leader in behavioral biometrics, ... grew to over 40 granted and pending patents. ... , , The Company,s IP ... System, Device, and Method Estimating Force Applied to a Touch Surface, ... costly hardware components needed to estimate the force and pressure applied to ...
(Date:12/7/2016)... , Dec. 7, 2016   Veridium ... announced the appointment of new CEO James ... executive with decades of experience, has served in ... Cisco, where he specialized in expanding a pipeline ... technology portfolios. He most recently served as managing ...
Breaking Biology News(10 mins):